NR4A1 and breast cancer: AI therapy brings about an approximately 90% reduction in the serum and tumor-tissue levels of E2 in postmenopausal women, which is the basis of the expression of the antitumor effects of AIs on hormone receptor-positive breast cancer cells [13-17].